Moderna expects to rake in $18.4bn (£13bn) of sales from its coronavirus vaccine this year, marking a huge turnaround in the fortunes of the US biotech firm. The expected revenue is far higher than the $11.2bn predicted by analysts, and exceeds the $15bn in sales that its US rival Pfizer expects for the Covid-19 vaccine that it developed with Germany’s BioNTech. […] The Moderna vaccine, similar to the Pfizer/BioNTech version, is based on re-engineering mRNA – the molecule that sends genetic instructions from DNA to a cell’s protein-making machinery – and it has produced equally strong results in late-stage clinical trials, with an efficacy of 94% . Moderna is the first company to have developed a new vaccine version designed to provide better protection against the highly contagious coronavirus variant identified in South Africa, and it shipped it to the US National Institutes of Health this week for testing as a booster shot . […] Moderna remains on track to deliver the first 100m doses by March and the second order of 100m doses in May.
Click here to read the full article